Lanicemine

Lanicemine
Clinical data
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (1S)-1-Phenyl-2-pyridin-2-ylethanamine;
CAS Number	153322-05-5;
PubChem CID	9794203;
IUPHAR/BPS	7681;
ChemSpider	7969970;
Chemical and physical data
Formula	C13H14N2
Molar mass	198.26 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2;
	InChI InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1; Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N;

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist developed by AstraZeneca,^[1] which was being studied for the management of severe and treatment-resistant depression.^[2] It was originally developed as a neuroprotective agent, but was redeveloped as an antidepressant following the observation that the NMDA receptor antagonist ketamine has potent antidepressant effects, but also has hallucinogenic side effects which make it unsuitable for use as an antidepressant in most circumstances. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.^[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.^[4]

References

^ US 6518432, Melvyn E. Giles, "Process"
^ "AstraZeneca Annual Report and Form 20-F Information 2012" (PDF).
^ Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. 74 (4): 257–264. doi:10.1016/j.biopsych.2012.10.019. PMC 3594049. PMID 23206319.
^ Flowers, Sophie. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company". Retrieved 6 February 2014.

[1] US 6518432, Melvyn E. Giles, "Process"

[2] "AstraZeneca Annual Report and Form 20-F Information 2012" (PDF).

[3] Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. 74 (4): 257–264. doi:10.1016/j.biopsych.2012.10.019. PMC 3594049. PMID 23206319.

[4] Flowers, Sophie. "Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of "momentum" for the company". Retrieved 6 February 2014.

[1]

[2]

[3]

[4]

See also

References